Chemence Medical Receives US food and drug clearance for adhesive-based wound closure pen

1 min read

Chemence Medical has announced it received US Food and Drug Administration clearance to market and sell the Exofin Precision Pen as a new medical device for wound closure.

The Exofin Precision Pen will enable medical providers greater versatility and exactness in closing wounds while also improving ease of use in applying topical skin adhesive.

“Whether it’s a substantial abdominal incision, a fine incision behind the ear or somewhere in between, the Exofin Precision Pen is ready to be that versatile tool for physicians to improve patient outcomes,” said Jeff Roberson, President of Chemence Medical.

“Doctors and surgeons emphasized they wanted an adhesive that could be applied with precision, regardless of the wound size or location, even in the most delicate procedures. We designed the Exofin Precision Pen to meet these needs by making it natural to hold, incorporating multiple applicators, and allowing doctors to vary the flow of adhesive with a pressure-controlled delivery system and higher viscosity formulation while maintaining the fast dry times of our other Exofin products.”

The Exofin Precision Pen is the only pen-style applicator on the market to feature an adjustable tip that allows the user to control the adhesive width by supporting three different application methods in a single device: a micro-bristle brush for wide coverage, an inverted brush for narrow lines, and an angle precision tip for micro lines. The Exofin Precision Pen also includes an ergonomic design with a grooved non-slip surface, a pressure-controlled variable adhesive flow rate and a transparent activation chamber for easily viewing the adhesive flow. The Exofin Precision Pen is said to provide a 14-day microbial barrier to improve recovery and allow patients to resume normal activities faster, including showering without special coverings or dressings.